Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACC: Cetuximab and Radiotherapy in Esophageal Cancer
NCT00827671Phase 2Terminated
- Start
- Mar 2009
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma. Primary endpoints: Pathological Complete Remission at 1 month and Resectability Rate at 6 months. Started Mar 2009; status: terminated.
02
Drugs
KL-140
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00827671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00827671.